Skip to main content
. 2015 Jul 2;75(1):75–83. doi: 10.1136/annrheumdis-2015-207511

Figure 1.

Figure 1

Patient disposition. *Patients who did not achieve an improvement of RA symptoms (defined as the persistence of DAS28[ESR] ≥3.2 for 4 weeks or longer) after Week 24 were eligible to withdraw from DB and move to rescue treatment with open label CZP. CZP, certolizumab pegol; DAS28, Disease Activity Score 28-joint assessment; DB, double blind; ESR, erythrocyte sedimentation rate; FAS, full analysis set; MTX, methotrexate; PBO, placebo; RA, rheumatoid arthritis.